Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
Status:
Recruiting
Trial end date:
2029-12-01
Target enrollment:
Participant gender:
Summary
This study assesses the safety and efficacy of repeat monthly dosing of super-selective
intra-arterial cerebral infusion (SIACI) of cetuximab and bevacizumab in patients < 22 years
of age.